424 related articles for article (PubMed ID: 37468932)
21. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes.
Cheng Z; Yuan Y; Han X; Yang L; Cai S; Yang F; Lu Z; Wang C; Deng H; Zhao J; Xiang Y; Correll CU; Yu X
J Psychopharmacol; 2019 Oct; 33(10):1227-1236. PubMed ID: 31487208
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
Li H; Luo J; Wang C; Xie S; Xu X; Wang X; Yu W; Gu N; Kane JM
Schizophr Res; 2014 Aug; 157(1-3):112-9. PubMed ID: 24994555
[TBL] [Abstract][Full Text] [Related]
23. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Smith RC; Leucht S; Davis JM
Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
[TBL] [Abstract][Full Text] [Related]
24. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH
J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749
[TBL] [Abstract][Full Text] [Related]
25. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
Correll CU; Zhao J; Carson W; Marcus R; McQuade R; Forbes RA; Mankoski R
J Am Acad Child Adolesc Psychiatry; 2013 Jul; 52(7):689-698.e3. PubMed ID: 23800482
[TBL] [Abstract][Full Text] [Related]
26. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.
Chan HY; Lin WW; Lin SK; Hwang TJ; Su TP; Chiang SC; Hwu HG
J Clin Psychiatry; 2007 Jan; 68(1):29-36. PubMed ID: 17284127
[TBL] [Abstract][Full Text] [Related]
28. Early Antipsychotic Nonresponse as a Predictor of Nonresponse and Nonremission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial.
Pagsberg AK; Krogmann A; Jeppesen P; von Hardenberg L; Klauber DG; Jensen KG; Rudå D; Decara MS; Jepsen JRM; Fagerlund B; Fink-Jensen A; Correll CU; Galling B
J Am Acad Child Adolesc Psychiatry; 2022 Aug; 61(8):997-1009. PubMed ID: 35026408
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
30. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial.
Zhao J; Song X; Ai X; Gu X; Huang G; Li X; Pang L; Ding M; Ding S; Lv L
PLoS One; 2015; 10(10):e0139717. PubMed ID: 26448615
[TBL] [Abstract][Full Text] [Related]
31. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
Adams DH; Kinon BJ; Baygani S; Millen BA; Velona I; Kollack-Walker S; Walling DP
BMC Psychiatry; 2013 May; 13():143. PubMed ID: 23694720
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
33. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
[TBL] [Abstract][Full Text] [Related]
35. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
36. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.
Ascher-Svanum H; Zhao F; Detke HC; Nyhuis AW; Lawson AH; Stauffer VL; Montgomery W; Witte MM; McDonnell DP
BMC Psychiatry; 2011 Sep; 11():152. PubMed ID: 21943257
[TBL] [Abstract][Full Text] [Related]
37. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.
Bervoets C; Morrens M; Vansteelandt K; Kok F; de Patoul A; Halkin V; Pitsi D; Constant E; Peuskens J; Sabbe B
CNS Drugs; 2012 Nov; 26(11):975-82. PubMed ID: 23018547
[TBL] [Abstract][Full Text] [Related]
38. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
39. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
[TBL] [Abstract][Full Text] [Related]
40. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
